Stock Evaluator: Biomerica, Inc. (BMRA)

Biomerica, Inc. BMRA

$1.59 0.00 0.00%
July 30, 2026 3:33:31 PM EST November 10, 2021 Volume: 106
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company’s diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Commentary & Analysis


Financial Summary

Share Statistics BMRA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $4.9 $334.8 3%
Shares Out (Mil) 3.0 41.7 10%
Institutional Ownership 26.1% 77.3% 12%
Float (Mil) 2.8 34.7 7%
Beta 0.29 0.86 17%
Avg Daily Volume (000s) 6 266 14%
Price Change
(52-week)
(53.8%) 60.7% 14%
Growth BMRA Industry
Median
Percentile
(All Stocks)
Sales (5yr) (4.6%) 11.8% 9%
Net Income (5yr) (16.8%) (5.8%) 23%
EPS (5yr) (3.3%) 10.7% 27
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (16.2%) (16.1%) 45%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials BMRA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $4 $152 5%
Net Income (TTM) (Mil) ($4) ($11) 34%
EPS (TTM) ($1.551) ($0.500) 17%
Operating Cash Flow (TTM) (Mil) ($3) ($2) 27%
Net Cash Flow (TTM) (Mil) na $1 na
Long-Term Debt (Q1) (Mil) $0 $22 0%
Enterprise Value (Q1) (Mil) $5 $304 6%
Valuation BMRA Industry
Median
Percentile
(All Stocks)
P/B 1.46 2.88 38%
P/E na 30.5 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.9 na
Ratios BMRA Industry
Median
Percentile
(All Stocks)
Gross Margin 4.4% 59.1% 6%
Net Margin (96.5%) (7.7%) 8%
ROA (68.1%) (13.7%) 8%
ROE (94.3%) (15.9%) 10%
Liabilities to Assets 32.0% 44.9% 23%
F-Score 3 4 19%

Biomerica, Inc. did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors